-
1 week ago | 
ajmc.com | Pieter Sonneveld |Mary Caffrey |Rose McNulty
The PERSEUS (NCT03710603) and CEPHEUS (NCT03652064) trials both demonstrated improved depth and duration of responses and progression-free survival (PFS) with a quadruplet regimen of daratumumab plus bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) in patients with multiple myeloma.1,2 Although these trials support the use of frontline daratumumab plus VRd in both transplant-eligible and transplant-ineligible patients, the median PFS for patients in these studies is...
-
Aug 27, 2024 | 
onclive.com | Pieter Sonneveld
CommentaryVideoAugust 27, 2024Author(s):Pieter Sonneveld, MD, PhD, discusses the background of the PERSEUS trial, which evaluated D-VRd for induction and consolidation in newly diagnosed myeloma.
-
Aug 22, 2024 | 
onclive.com | Pieter Sonneveld
CommentaryVideoAugust 22, 2024Author(s):Pieter Sonneveld, MD, PhD, discusses the potential of quadruplet therapeutic regimens in the frontline management of multiple myeloma. Pieter Sonneveld, MD, PhD, professor, hematology, Erasmus University of Rotterdam, Erasmus Medical Center; chairman, HOVON Multiple Myeloma Working Group, European Myeloma Network, discusses the feasibility of investigating quadruplet therapeutic regimens in the frontline treatment of patients with multiple myeloma.
-
Aug 20, 2024 | 
onclive.com | Pieter Sonneveld
CommentaryVideoAugust 20, 2024Author(s):Pieter Sonneveld, MD, PhD, discusses the FDA approval of daratumumab plus VRd for select patients with newly diagnosed multiple myeloma.
-
Aug 11, 2024 | 
nature.com | Charlotte Pawlyn |Fredrik Schjesvold |David Cairns |Maria-Victoria Mateos |Jacob P. Laubach |Katja Weisel | +4 more
AbstractMeasurement of overall survival (OS) remains the gold standard for interpreting the impact of new therapies for multiple myeloma in phase 3 trials. However, as outcomes have improved, it is increasingly challenging to use OS as the primary endpoint if timely approval of novel agents is to be ensured to enable maximum benefit for patients.
-
Apr 10, 2024 | 
nature.com | Pieter Sonneveld
AbstractHuman bone marrow permanently harbors high numbers of neutrophils, and a tumor-supportive bias of these cells could significantly impact bone marrow-confined malignancies. In individuals with multiple myeloma, the bone marrow is characterized by inflammatory stromal cells with the potential to influence neutrophils. We investigated myeloma-associated alterations in human marrow neutrophils and the impact of stromal inflammation on neutrophil function.
-
Feb 28, 2024 | 
futuremedicine.com | Luciano Costa |Thomas W. LeBlanc |Thomas Leblanc |Hans Tesch |Pieter Sonneveld
Multiple myeloma (MM) is a progressive type of malignancy characterized by the rapid accumulation of monoclonal plasma cells mostly in the bone marrow [1]. Patients with MM experience a range of physical symptoms, including pain and fatigue, with many also reporting depression, anxiety and impairment of psychosocial well-being [2,3]. Unfortunately, the long-term prognosis is often poor for these patients, with median survival estimates ranging only from 5 to 7 years [1].
-
Dec 13, 2023 | 
bpno.dk | Pieter Sonneveld
december 2023 Pieter Sonneveld discussed in this MEDtalk the PERSEUS trial presented at ASH 2023. The study involved 700 patients across 13 countries and showed promising results in progression-free survival, higher complete response rates, and substantial MRD negativity for transplant-eligible patients with Multiple Myeloma.
-
Dec 7, 2023 | 
nature.com | Elias K. Mai |Hans Salwender |Marc S. Raab |Katia Mancuso |Meral Beksac |Ullrich Graeven | +6 more
AbstractEarly morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005–2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both.
